GlassScriptPhysician profile
Jatin Bidani
NPI 1770544298
$4,235.17
in general payments reported to CMS, 2019-2025
33 companies · $876 in 2025
The $876 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.52 · 2020: $912 · 2021: $463 · 2022: $819 · 2023: $579 · 2024: $566 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,021.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $923.40 | 2021-2025 | Skyrizi, Linzess, Creon |
| Conmed Corporation | $800.00 | 2020 | |
| Janssen Biotech, INC. | $523.76 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Neuraxis, INC. | $316.08 | 2025 | |
| Gilead Sciences, INC. | $231.75 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.08 | 2019-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $182.73 | 2020-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $156.49 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $137.46 | 2020-2025 | Sutab, Suflave |
| Novo Nordisk INC | $115.24 | 2025 | Wegovy |
| Celgene Corporation | $112.93 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $70.54 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $65.07 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $48.81 | 2025 | Dupixent |
| Shield Therapeutics INC | $43.59 | 2023 | Accrufer |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.95 | 2022 | |
| Boston Scientific Corporation | $29.66 | 2023 | Cre Pro |
| Alnylam Pharmaceuticals INC. | $24.45 | 2025 | Givlaari |
| E.R. Squibb & Sons, L.L.C. | $24.07 | 2024 | Zeposia |
| Mauna Kea Technologies, INC. | $22.20 | 2024 | |
| Pfizer INC. | $21.53 | 2025 | |
| Aimmune Therapeutics, INC. | $21.06 | 2025 | Zenpep |
| Ardelyx, INC. | $19.54 | 2023 | Ibsrela |
| Vivus LLC | $18.81 | 2022 | |
| Madrigal Pharmaceuticals | $18.66 | 2024 | Resmetirom |
| Capsovision, INC. | $18.11 | 2025 | Capsocam Plus |
| Intra-Sana Laboratories | $16.86 | 2022 | |
| Mallinckrodt Hospital Products INC. | $15.83 | 2023 | Terlivaz |
| Echosens North America, INC. | $13.98 | 2023 | Fibroscan |
| Alfasigma USA, INC. | $11.89 | 2020 | |
| Thd America, INC. | $9.64 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jatin Bidani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.